Hook & thesis
ASML is the backbone of advanced chip-making - the only company that mass-produces extreme ultraviolet (EUV) lithography machines. That monopoly has turned ASML into a poster child for the AI hardware boom: recent quarterly commentary points to 55% revenue growth and 113 systems sold in the most recent quarter, with customer orders stretching into 2029-2030. Those headlines are real and meaningful.
But headlines and backlog visibility aren’t the same as profitable, uninterrupted growth. The market currently prices ASML like a perpetual monster-growth machine (market cap $605.7 billion, P/E ~41x). I believe investors are underestimating two linked realities: capacity will take time to scale meaningfully, and technology/cost cycles in the supply chain can create a near-term hangover that forces a re-pricing. That creates a tactical short opportunity with a clearly defined risk/reward.
What ASML does and why the market cares
ASML develops, produces, sells and services lithography systems - primarily EUV machines - plus metrology and inspection equipment used to make leading-edge semiconductors. The company’s systems are mandatory for advanced nodes that power high-performance AI accelerators. Because only ASML can supply EUV at scale, it sits at the center of the AI hardware supply chain: when data-center customers accelerate chip builds, ASML’s order book jumps.
That centrality is why even modest shifts in ASML’s supply or demand picture ripple across chips and AI-infrastructure stocks. The market cares because ASML’s revenue cadence and capacity plans are effectively a high-fidelity indicator of how fast leading-edge fabs can ramp, and therefore how quickly Nvidia, Micron and other AI-reliant firms can scale deployments.
Numbers that matter
- Recent quarter: revenue grew ~55% to €11.66 billion and ASML sold 113 lithography systems, nearly double year-ago unit sales.
- Order visibility: customers are placing orders extending to 2029-2030, with company commentary suggesting supply constraints into 2027-2028 and a planned capacity increase of roughly 30% in 2027.
- Valuation and size: market capitalization ~$605.7 billion, trailing P/E ~41.26 and P/B ~25.79 - both reflect a premium for ASML’s monopoly pricing power.
- Balance-sheet context: shares outstanding ~388.1 million; float ~385.3 million. Dividend per share is $1.791518, with an ex-dividend date of 10/27/2026.
- Technical snapshot: current price $1566.66, 52-week high $1999.96, low $946.11; 10-day SMA ~$1671.25, RSI ~33.56 and MACD in bearish momentum (MACD line -31.7 vs signal -11.09).
- Trading/sentiment: average volume ~1.62M; recent short-volume days show elevated activity (for example on 10/14 short volume ~487k of ~975k total volume), and reported short interest sits around 1.45M as of 9/30/2026 (days to cover ~1.05).
Why an AI “bottleneck” can turn into downside
There’s a subtle but important distinction between strong demand and smoothly realizable revenue. ASML’s backlog and multi-year order visibility are real, but converting demand into delivered revenue requires manufacturing capacity, sub-supplier availability, and stable pricing for service and upgrades. Management’s plan to raise capacity by ~30% in 2027 is meaningful but not instantaneous. If demand growth slows from its current pace or if customers delay shipments/acceptances because of their own inventory management, upgrades and installations, a backlog that today looks like a floor can become a timing risk.
Combine that timing risk with a stretched valuation: the stock already assumes years of high-growth, high-margin performance. Any credibility gap between order-book optimism and delivery execution - even if temporary - can drive a sharp re-rating given the premium multiple investors have afforded ASML.
Valuation framing
| Metric | Value |
|---|---|
| Current price | $1566.66 |
| Market cap | $605.7B |
| P/E (trailing) | ~41.26 |
| P/B | ~25.79 |
| Recent quarterly revenue | €11.66B (Q3) |
ASML trades at premium multiples that bake in continued margin and revenue growth. That can be rational - the company produces indispensable capital equipment - but it also means downside is amplified if growth expectations slip or timelines elongate. A move from the present multiple back toward a more conservative multiple (for instance in the mid-20s P/E for capital-equipment cyclicality) would translate to a sizable stock decline absent offsetting earnings upside.
Catalysts that could accelerate the move lower
- Delivery slowdowns or missed capacity targets in 2027 - any delay to the planned ~30% capacity increase would force customers to reschedule and could push revenue recognition later.
- Evidence of chip-fab inventory adjustments among hyperscalers - if major customers signal slower build-outs, order timings could compress.
- Macro shock to capex (higher rates or weaker cloud demand) that causes customers to push out purchases despite long order books.
- Upgrade deferrals - a meaningful portion of near-term revenue is tied to upgrades and service; if customers pause upgrades, revenue growth stalls faster than hardware shipments alone.
- Speculative catalyst: chatter or action on a stock split could initially boost retail demand, but a split without fundamental capacity improvements could amplify volatility and subsequent pullback.
Trade plan - tactical short
Direction: Short ASML
Entry: $1566.66
Target: $1250.00
Stop loss: $1750.00
Horizon: mid term (45 trading days) - I expect any meaningful re-pricing to play out within roughly two months as order flow clarity and capacity announcements filter through earnings calls and supplier commentary.
Rationale: Entry is at the recent trading level where momentum has turned negative (price below 10/21/50-day EMAs, MACD bearish, RSI at ~33). Target $1250 sits well above the 52-week low but represents a ~20% decline from entry, a realistic repricing if forward growth gets trimmed or delivery timing stretches. Stop at $1750 protects against upside spikes and is above recent moving averages and the prior short-term consolidation range - it limits loss if bullish news (stronger-than-expected order fill or split speculation) re-accelerates the rally.
Risk management & position sizing
This trade should be sized for a high-risk, event-driven short. Use tight position sizing so that a stop-hit does not materially dent capital. Monitor daily volume and short-volume metrics - if days-with-large-short-volume flip to heavy cover, reduce size quickly.
Risks and counterarguments
- Persistent strong demand: The simplest counterargument is that demand remains stronger-than-expected. Management noted customers have orders into 2029-2030 and sold 113 systems in the latest quarter. If those bookings convert to revenue faster than I assume, the re-rating I’m betting on may not occur.
- Monopoly pricing and margin resilience: ASML’s pricing power and gross margin (~54% referenced in recent coverage) give it the ability to absorb near-term hiccups without earnings falling as much as a cyclical supplier would.
- Supply-chain improvements or capacity acceleration: If ASML accelerates capacity beyond the stated ~30% 2027 plan or suppliers scale faster, the timing risk evaporates and the stock regains momentum.
- Macro tailwinds for capex: A renewed wave of cloud spending or incentives for domestic chip production could push fabs to accelerate buildouts, supporting ASML revenues and invalidating the short thesis.
- Short squeeze risk: Short interest is not enormous (days-to-cover ~1), but elevated short-volume days suggest squeeze dynamics could still create quick, painful moves higher on any surprise positive news.
Counterargument I respect: ASML’s monopoly on EUV makes it structurally different from cyclical capex vendors. Even with timing hiccups, the company’s long-term cash generation and pricing power could absorb near-term delivery issues and leave the share price resilient. If management demonstrates faster-than-expected capacity build or if customers accelerate purchases, the stock will likely re-rate higher.
Conclusion - stance and what would change my mind
My base case: a mid-term downside repricing is more likely than not because current multiples already assume a flawless multi-year scale-up of capacity and margins. The trade is a tactical short from $1566.66 to $1250.00 with a stop at $1750.00, horizon ~45 trading days. This is a high-risk trade that profits from a timing mismatch between demand and achievable throughput.
I would change my view if one or more of the following occurred: management provides credible and independently audited acceleration of capacity beyond the 30% 2027 plan; customer commentary shows materially stronger-than-expected acceptance schedules; or quarterly revenue and margin prints beat estimates by a wide margin while management tightens delivery timelines. Any of those would push me to flatten the short and reconsider a long exposure.
Trade with defined risk, watch the order-flow narrative closely, and always size so a stop is tolerable.